Atsushi Kambayashi
Overview
Explore the profile of Atsushi Kambayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
86
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beran K, Abrahamsson B, Charoo N, Cristofoletti R, Holm R, Kambayashi A, et al.
J Pharm Sci
. 2024 Nov;
114(2):660-680.
PMID: 39547650
According to the ICH M9 Guideline, the triazole antifungal voriconazole is a Biopharmaceutics Classification System (BCS) class II drug, being highly soluble at the highest dose strength but not at...
2.
Beran K, Abrahamsson B, Charoo N, Cristofoletti R, Holm R, Kambayashi A, et al.
J Pharm Sci
. 2024 Oct;
114(2):644-659.
PMID: 39454947
Lemborexant is a dual orexin receptor antagonist assigned to class II of the Biopharmaceutics Classification System (BCS). Thus, the ICH M9 Guideline excludes immediate-release (IR) solid oral dosage forms containing...
3.
Takahashi Y, Kambayashi A
Eur J Pharm Biopharm
. 2024 Sep;
204:114479.
PMID: 39233190
Establishing an in vitro - in vivo correlation (IVIVC) for oral modified release (MR) formulations would make it possible to substitute an in vitro dissolution test for human bioequivalence (BE)...
4.
Kambayashi A, Iida M, Ishihara M, Takahashi Y, Abrahamsson B, Charoo N, et al.
J Pharm Sci
. 2024 Aug;
113(11):3137-3144.
PMID: 39154736
The present monograph discusses the possibility of BCS-based biowaivers for immediate release pharmaceutical products containing raltegravir potassium, which is used to treat human immunodeficiency virus (HIV) infections. Raltegravir potassium can...
5.
Charoo N, Selvasudha N, Kath Z, Abrahamsson B, Cristofoletti R, Kambayashi A, et al.
J Pharm Sci
. 2024 Jun;
113(9):2981-2993.
PMID: 38857646
In this monograph, the potential use of methods based on the Biopharmaceutics Classification System (BCS) framework to evaluate the bioequivalence of solid immediate-release (IR) oral dosage forms containing fexofenadine hydrochloride...
6.
Nakamura K, Kambayashi A, Onoue S
Pharm Res
. 2024 Mar;
41(4):673-685.
PMID: 38472609
Purpose: The purpose of this study was to develop a simulation model for the pharmacokinetics (PK) of drugs undergoing enterohepatic circulation (EHC) with consideration to the environment in the gastrointestinal...
7.
Shirasaka Y, Kambayashi A
Drug Metab Pharmacokinet
. 2023 Dec;
54:100533.
PMID: 38118335
No abstract available.
8.
Plano D, Rudolph N, Saal C, Abrahamsson B, Cristofoletti R, Kambayashi A, et al.
J Pharm Sci
. 2023 Nov;
113(2):386-395.
PMID: 37951471
A Biopharmaceutics Classification System (BCS)-based biowaiver monograph is presented for isavuconazonium sulfate. A BCS-based biowaiver is a regulatory option to substitute appropriate in vitro data for in vivo bioequivalence studies....
9.
Makino K, Tsukada R, Kambayashi A, Yamada K, Sato H, Onoue S
Biopharm Drug Dispos
. 2023 Aug;
44(6):387-395.
PMID: 37526477
The present study was undertaken to develop a self-micellizing solid dispersion (SMSD) of tacrolimus (TAC) to improve the biopharmaceutical properties of TAC. An SMSD formulation of TAC (SMSD/TAC) and amorphous...
10.
Kambayashi A
Mol Pharm
. 2023 Jul;
20(9):4344-4353.
PMID: 37523273
Optimization of the in vivo performance of dosage forms in humans is essential in developing not only conventional formulations but also drug delivery system (DDS) formulations. Although animal experiments are...